The relationship between inflammation markers, positron emission tomography/ /computed tomography parameters and disease prognosis in advanced non-small-cell lung cancer patients

被引:0
|
作者
Pirincci, Esra [1 ]
Oruc, Zeynep [2 ]
Ebinc, Senar [3 ,6 ]
Guzel, Yunus [4 ]
Komek, Halil [4 ]
Kucukoner, Mehmet [5 ]
Urakci, Zuhat [2 ]
Kaplan, Muhammet Ali [2 ]
Tasdemir, Bekir [5 ]
Isikdogan, Abdurrahman
机构
[1] Dicle Univ, Fac Med, Dept Hematol, Diyarbakir, Turkiye
[2] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkiye
[3] Gazi Yasargil Training & Res Hosp, Dept Med Oncol, Diyarbakir, Turkiye
[4] Gazi Yasargil Training & Res Hosp, Dept Nucl Med, Diyarbakir, Turkiye
[5] Dicle Univ, Fac Med, Dept Nucl Med, Diyarbakir, Turkiye
[6] Gazi Yasargil Training & Res Hosp, Dept Med Oncol, Billst Sur, TR-21280 Diyarbakir, Turkiye
来源
ONCOLOGY IN CLINICAL PRACTICE | 2024年 / 20卷 / 04期
关键词
inflammation; non-small-cell lung cancer; PET/CT; LYMPHOCYTE RATIO; NEUTROPHIL; MUTATIONS; SURVIVAL; OUTCOMES; PET/CT;
D O I
10.5603/ocp.97451
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Inflammation is known to be related to the development, spread, prognosis, and treatment response in cancer patients. Our study aimed to evaluate the correlation between inflammation indices and positron emission tomography-computed tomography (PET/CT) parameters and investigate their relationship with progression-free survival (PFS) and overall survival (OS) in patients diagnosed with stage-IV non -small cell lung cancer (NSCLC). Material and methods. Demographic, clinicopathological, laboratory, and PET/CT data of 179 patients diagnosed with stage-IV NSCLC who presented to the Oncology Department of Dicle University, Faculty of Medicine between 2010-2020 were retrieved from patient files and the hospital database system. Results. The median age at diagnosis was 64 (27-87) years. All patients included in the study had NSCLC: 72.6% had adenocarcinoma, 21.2% had squamous cell carcinoma, and 6.1% had other histological types. Of the 78 patients who were subjected to molecular analysis, 26 (33.3%) were EGFR-mutation positive. During the 10-month median follow-up, median first -line PFS was 6 months (95% CI 5.00-6.99), and median OS was 10 months (95% CI 7.8-12.1). The multivariate analysis performed for first -line PFS determined hemoglobin (HR = 1.01; 95% CI 1.003-1.02; p = 0.005) and PET total lesion glycolysis (TLG) (HR = 1.002; 95% CI 1.001-1.003; p = 0.003) values as independent prognostic factors. The multivariate analysis for OS determined positive EGFR mutation status (HR = 0.385; 95% CI 0.213-0.696; p = 0,014) and performance status (HR = 1.88; 95% CI 1.092-3.238; p = 0,008) as independent prognostic factors. Conclusions. Our study determined the hemoglobin level and PET TLG from PET/CT parameters to be independent prognostic factors for PFS, and performance status and EGFR mutation positivity to be independent prognostic factors for OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Mediastinal staging in non-small-cell lung carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography
    Harders, Stefan Walbom
    Madsen, Hans Henrik
    Hjorthaug, Karin
    Arveschoug, Anne Kirstine
    Rasmussen, Torben Riis
    Meldgaard, Peter
    Hoejbjerg, Johanne Andersen
    Pilegaard, Hans Kristian
    Hager, Henrik
    Rehling, Michael
    Rasmussen, Finn
    CANCER IMAGING, 2014, 14
  • [32] POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IMAGING FOR NON-SMALL CELL LUNG CANCER: A BUDGET IMPACT ANALYSIS
    Wichmann, R. M.
    Freitas, M. G.
    Silva, M. T.
    VALUE IN HEALTH, 2014, 17 (07) : A623 - A623
  • [33] Positron Emission Tomography-Computed Tomography for Postoperative Surveillance in Non-Small Cell Lung Cancer DISCUSSION
    Hofstetter, Wayne L.
    Choi
    Shrager, Joseph B.
    Kim, Young Tae
    Marshall, M. Blair
    ANNALS OF THORACIC SURGERY, 2011, 92 (05): : 1832 - 1832
  • [34] Role of Positron Emission Tomography in the Early Prediction of Response to Chemotherapy in Patients With Non-Small-Cell Lung Cancer
    Skoura, Evangelia
    Datseris, Ioannis E.
    Platis, Ioannis
    Oikonomopoulos, Georgios
    Syrigos, Konstantinos N.
    CLINICAL LUNG CANCER, 2012, 13 (03) : 181 - 187
  • [35] Positron emission tomography-Computed tomography for staging of mediastinal lymph nodes in patients with non-small cell lung cancer
    Prisadov, Georgi
    Blume-Vulin, Anja
    Scharpenberg, Martin
    Welcker, Katrin
    Kesieme, Emeka Blessius
    Linder, Albert
    ANNALS OF AFRICAN MEDICINE, 2023, 22 (01) : 101 - 106
  • [36] Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer
    von Haag, DW
    Follette, DM
    Roberts, PF
    Shelton, D
    Segel, LD
    Taylor, TM
    JOURNAL OF SURGICAL RESEARCH, 2002, 103 (02) : 160 - 164
  • [37] The value of positron emission tomography in patients with non-small cell lung cancer
    Kee, Frank
    Erridge, Sara
    Bradbury, Ian
    Cairns, Karen
    EUROPEAN JOURNAL OF RADIOLOGY, 2010, 73 (01) : 50 - 58
  • [38] 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients
    Toba, Hiroaki
    Sakiyama, Shoji
    Otsuka, Hideki
    Kawakami, Yukikiyo
    Takizawa, Hiromitsu
    Kenzaki, Koichiro
    Kondo, Kazuya
    Tangoku, Akira
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2012, 15 (05) : 859 - 864
  • [39] Prognostic Value of Tumor Dissemination (Dmax) Derived from Basal 18F-FDG Positron Emission Tomography/Computed Tomography in Patients with Advanced Non-Small-Cell Lung Cancer
    Pellegrino, Sara
    Fonti, Rosa
    Morra, Rocco
    Di Donna, Erica
    Servetto, Alberto
    Bianco, Roberto
    Del Vecchio, Silvana
    BIOMEDICINES, 2025, 13 (02)
  • [40] Predictive value of F-18-fluorodeoxyglucose positron emission tomography - computed tomography compared to postoperative pathological findings for patients with non-small-cell lung cancer
    Xue, Jie
    Zheng, Jinsong
    Guo, Hongbo
    Wang, Xiaohui
    Han, Anqin
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (01) : 109 - 114